Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PROSCA/BLADDR 2020 | Second-line treatment of mHSPC

Ursula Vogl • 7 Oct 2020
PROSCA/BLADDR 2020
Genitourinary Cancer Prostate Cancer

Ursula Vogl, MD, Ente Ospedaliero Cantonale (EOC), Ticino, Switzerland, explores the difficulties of sequencing second-line therapies for metastatic hormone-sensitive prostate cancer (mHSPC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Ursula Vogl

1:35
Unmet needs in mHSPC
Ursula Vogl • 7 Oct 2020
1:41
Challenges and treatment advances in mHSPC
Ursula Vogl • 14 Oct 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals